Coretec Group Inc Stock Price, News & Analysis

The Coretec Group, Inc. (OTCQB: CRTG) has signed an agreement with the French Alternative Energies and Atomic Energy Commission (CEA) to assess its Cyclohexasilane (CHS) for silicon anode production. CEA will investigate optimizing silicon nanowire growth, characterizing products, and comparing CHS-derived nanowires with those created using diphenyl silane. The collaboration could revolutionize silicon anode fabrication, potentially enhancing performance in lithium-ion batteries. Dr. Pascale Chenevier will lead this research, leveraging her extensive experience in energy nanoscience.

The Coretec Group, Inc. (OTCQB: CRTG) has filed a patent for surface-functionalized silicon quantum dots that generate ultraviolet (UV) light. This technology aims to transform UV lighting applications across various industries, including disinfection and agriculture. Dr. Ramez Elgammal noted the innovative potential of this advancement, while CEO Matt Kappers emphasized its role in expanding the company's technology portfolio. Silicon-based LEDs present significant benefits over traditional mercury-based options, highlighting the company's commitment to sustainable technological development.

The Coretec Group, Inc. (OTCQB: CRTG) has appointed Matthew Kappers as CEO, alongside his role on the board of directors. Kappers, previously a consultant for two and a half years and a partner at Concordia Financial Group, brings extensive experience to the role. The company recently closed a $6 million private placement, aiming to utilize these funds for the expansion of CHS technology and other corporate purposes. Michael Kraft transitions to President, focusing on commercialization and the IP portfolio of CHS.

The Coretec Group (OTCQB: CRTG) has partnered with Eindhoven University of Technology to advance patents on Cyclohexasilane (CHS). TU/e will conduct research on CHS to compare its deposition rates and film quality against other silanes for semiconductor processing. Led by Dr. Erik Bakkers, the lab aims to validate CHS's potential in low-temperature light-emitting silicon applications. The Coretec Group is also collaborating with Evonik for CHS production and is focused on expanding its patent portfolio.

The Coretec Group, Inc. (OTCQB: CRTG) announces Dr. Ramez Elgammal's selection to present at the AVS 21st International Conference on Atomic Layer Deposition on June 28, 2021. His abstract, focusing on innovative production methods for high purity silicon films using cyclohexasilane, highlights advancements in semiconductor technology. Dr. Elgammal emphasizes cyclohexasilane’s potential to enhance silicon precursor efficiency in microelectronic device manufacturing. The company aims to leverage engineered silicon for various applications, including electric vehicle batteries and solid-state lighting.

The Coretec Group, Inc. (OTCQB: CRTG) has filed a provisional patent for innovative applications of its Cyclohexasilane (CHS) in next-generation silicon anode battery technology. This marks the third patent filing in two years, enhancing Coretec’s intellectual property portfolio. The patent targets four distinct applications, addressing limitations in lithium-ion batteries, such as poor charge capacity and cycle life, and proposes solutions to issues like expansion and cell damage. Coretec aims to leverage its novel methods to improve cycling stability and capacity loss across various silicon anodes.

The Coretec Group Inc. (OTCQB:CRTG) announces a significant milestone in scaling the production of Cyclohexasilane (CHS) from 5g to 500g, marking a 100-fold increase in manufacturability. This advancement paves the way for commercial scale applications, with samples set to be shipped to evaluation customers in Europe and the U.S. The CEO, Michael Kraft, noted the successful progress despite pandemic challenges, and the response from customers has been enthusiastic. The evaluations aim to validate CHS's value in applications related to energy and technology markets.

The Coretec Group (OTCQB:CRTG) has successfully closed a private placement offering of 75 million shares of common stock and associated warrants, raising approximately $6 million at $0.08 per share. The warrants, exercisable at the same price, expire in five and a half years. The Company plans to use the net proceeds to enhance its CHS technology and for general corporate purposes. An initial registration statement is to be filed with the SEC within 20 days to cover the resale of these securities.

The Coretec Group (OTCQB:CRTG) has entered into a securities purchase agreement with a single institutional investor for a private placement of 75,000,000 shares and warrants to acquire an additional 82,500,000 shares. The deal, priced at $0.08 per share, is expected to yield gross proceeds of $6 million. Proceeds will primarily be used to further the development of CHS technology and for working capital. The offering is anticipated to close around March 5, 2021, pending customary conditions. The registration of shares is required within 20 days under SEC regulations.